Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Q: How do the Biomea (BMEA) stock options vest?

The options vest 1/16 per quarter over four years, subject to continued employment.

Q: Under which plan were the Biomea (BMEA) options granted?

The award was made under the company’s 2023 Inducement Equity Plan adopted November 17, 2023.

Q: Does the announcement report any cash payment or additional financial terms for BMEA?

No cash amounts or additional financial terms beyond the 7,500-share option grant and vesting schedule were disclosed.

Biomea Fusion (Nasdaq: BMEA) announced an inducement equity award granted by its compensation committee on November 26, 2025.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Biomea Fusion (Nasdaq: BMEA) announced an inducement equity award granted by its compensation committee on November 26, 2025. One new employee received non-qualified stock options to purchase 7,500 shares of common stock under the company’s 2023 Inducement Equity Plan. Shares vest at 1/16 per quarter over four years, subject to continued employment. The award was granted as an inducement material to the employee entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan was adopted by the board on November 17, 2023.

Argus Dec 2 session

-5.22% close to close Open Argus

Details

News Market Reaction – BMEA

On Dec 2, the first trading day after this news, BMEA closed 5.22% below the previous close.

Data tracked by StockTitan Argus for the Dec 2 session.

Key Figures

Inducement options: 7,500 shares Q3 2025 net loss: $16.4M Q3 2025 EPS: $0.27 loss per share +5 more

Inducement options: 7,500 shares; Non-qualified stock options granted to one new employee on November 26, 2025
Q3 2025 net loss: $16.4M; Net loss reported in Q3 2025 10-Q filing
Q3 2025 EPS: $0.27 loss per share; Basic and diluted loss per share in Q3 2025
Operating expenses: $20.8M; Q3 2025 operating expenses after reduced R&D spend
Interest & other income: $4.4M; Q3 2025 interest and other income
Cash balance: $47.0M; Cash, cash equivalents and restricted cash as of September 30, 2025
October 2025 offering proceeds: $25.0M; Approximate gross proceeds from October 6, 2025 public offering
Shares outstanding: 70,703,639 shares; Shares outstanding as of October 31, 2025

Historical Context

5 past events · Latest: Dec 09

5 events

Dec 09
KOL presentation

24h Move

-0.7%

KOL interview and WCIRDC presentation highlighting menin inhibitors and icovamenib.
Dec 05
Clinical data update

24h Move

+3.9%

COVALENT-111 data showing durable glycemic and C-peptide improvements with icovamenib.
Dec 01
Conference presentation

24h Move

-7.3%

Announcement of oral presentation of week 52 icovamenib data at WCIRDC.
Dec 01
Inducement option grant

24h Move

-7.3%

Inducement stock options for 7,500 shares under the 2023 Inducement Equity Plan.
Nov 24
Investor conferences

24h Move

+2.9%

Planned participation in December healthcare investor conferences and related meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, Nasdaq Listing Rule 5635(c)(4), Inducement Equity Plan

3 terms

non-qualified stock options financial

"granted one new employee non-qualified stock options to purchase 7,500 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

Inducement Equity Plan financial

"under Biomea’s 2023 Inducement Equity Plan (the “Plan”)"

An inducement equity plan is a program that offers employees or executives new stock options or shares as a way to encourage them to join or stay with a company. It acts like a reward or incentive to motivate performance and loyalty, aligning their interests with the company's success. For investors, such plans can influence a company's share structure and future earnings, making them an important factor to consider.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

12/01/2025 - 04:05 PM

SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase 7,500 shares of the Company’s common stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to such employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).

The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.

About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.

Contact:
Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biomea Fusion (BMEA) grant on November 26, 2025?

Biomea granted one new employee non-qualified stock options to purchase 7,500 shares of common stock.

How do the Biomea (BMEA) stock options vest?

The options vest 1/16 per quarter over four years, subject to continued employment.

Under which plan were the Biomea (BMEA) options granted?

The award was made under the company’s 2023 Inducement Equity Plan adopted November 17, 2023.

Why was the Biomea (BMEA) award classified as an inducement?

It was granted as an inducement material to the employee entering employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Does the announcement report any cash payment or additional financial terms for BMEA?

No cash amounts or additional financial terms beyond the 7,500-share option grant and vesting schedule were disclosed.

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)